Nxera Pharma Co., Ltd. (FRA:JSS)
Germany · Delayed Price · Currency is EUR | Market Cap | 526.47M +2.6% |
| Revenue (ttm) | 186.69M +10.9% |
| Net Income | -54.42M |
| EPS | -0.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 5.40 |
| Previous Close | 5.65 |
| Day's Range | 5.40 - 5.40 |
| 52-Week Range | 4.04 - 6.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Nxera Pharma
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychi... [Read more]
Financial Performance
In 2025, Nxera Pharma's revenue was 29.62 billion, an increase of 2.71% compared to the previous year's 28.84 billion. Losses were -12.53 billion, 159.0% more than in 2024.
Financial numbers in JPY Financial StatementsNews
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the Je...
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company (“N...
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) ...
Nxera Pharma Quarterly report: Q1 2026
Nxera Pharma has published its Q1 2026 quarterly earnings report on May 1, 2026.
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discov...
Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical d...
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a...
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 09 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target ...
Nxera Pharma Slides: Corporate presentation
Nxera Pharma has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development mi...
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry o...
Nxera Pharma Proposes Changes to its Board of Directors
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated be...
Nxera Pharma Earnings Call Transcript: Q4 2025
FY 2025 saw revenue growth to JPY 29.6B, led by strong product sales, but operating losses due to higher R&D and restructuring costs. FY 2026 targets include profitability, cost reduction, and continued commercial growth, with upside from milestone deals and new product launches.
Nxera Pharma Quarterly report: Q4 2025
Nxera Pharma has published its Q4 2025 quarterly earnings report on February 13, 2026.
Nxera Pharma Slides: Q4 2025
Nxera Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 13, 2026.
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the...
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone ass...
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly esta...
Nxera Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
NxWave platform drives a robust pipeline, with strong commercial growth in Japan and new rare disease assets like vamorolone. Two Phase II-ready programs are set for partnering, and key milestones from Neurocrine, Centessa, and collaborations are expected by 2026.
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated...
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, ...
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to ex...
Nxera Pharma Slides: Corporate presentation
Nxera Pharma has posted slides in relation to its latest quarterly earnings report, which was published on December 17, 2025.
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that its Board of Directors have decided to replace the current Restricted Share U...